Search Results
Aug 05, 2026, 09:05 ET RECKITT ANNOUNCES U.S. FDA APPROVAL OF MUCINEX® 12HR COLD & FEVER MULTI-SYMPTOM, THE FIRST OTC INNOVATION IN THE COLD & FLU CATEGORY IN 14 YEARS
Mucinex® 12HR Cold & Fever Multi-Symptom is the first U.S. Food and Drug Administration (FDA)-approved over-the-counter (OTC) innovation in the cold and flu category in 14 years, and the first New Drug Application (NDA) under the Reckitt name to receive FDA approval.1 Developed
More news about: Reckitt
Aug 05, 2026, 09:02 ET Clarity Pharmaceuticals Announces SECuRE Trial Update on 8 GBq 67Cu-SAR-bisPSMA dose level with two additional complete responses
safety and efficacy of 67Cu-SAR-bisPSMA and 64Cu-SAR-bisPSMA have not been assessed by health authorities such as the US Food and Drug Administration (FDA) or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.About
More news about: Clarity Pharmaceuticals
Aug 05, 2026, 08:33 ET Aveva Drug Delivery Systems Prevails on Appeal, Federal Circuit Affirms Non-Infringement of ZTlido® Patents - Prepares for an Imminent Launch of its Generic Product with 180 Day Exclusivity
commercial launch of its generic lidocaine topical system 1.8% product, which will enjoy 180 day exclusivity.About Aveva Drug Delivery SystemsAveva Drug Delivery Systems (a DifGen company) is a fully integrated developer and manufacturer of sterile products, Transdermal Delivery Systems
More news about: DifGen Pharmaceuticals LLC
Aug 05, 2026, 08:30 ET NNN REIT, Inc. Announces Second Quarter 2026 Results
13.Drug stores
More news about: NNN REIT, Inc.
Aug 05, 2026, 08:07 ET Buzz Health Wins Bronze Stevie® Award for Technology That Lowers Prescription Costs
RxCompare and its SmartBIN routing engine recognized for Technical Innovation of the Year, surfacing the best available drug price in under 2 secondsFORT WALTON BEACH, Fla., Aug. 5, 2026 /PRNewswire/ --
More news about: Buzz Health
Aug 05, 2026, 08:05 ET Accord Healthcare Launches Sugammadex Injection, Expanding Access to Neuromuscular Blockade Reversal During Surgery
or administration of medicines that potentiate neuromuscular blockade may lead to recurrence of muscle weakness and respiratory compromise.Drug interaction effects. Concomitant use of certain medications, including toremifene, may delay recovery. Sugammadex may also reduce the effectiveness
More news about: Accord Healthcare US
Aug 05, 2026, 08:01 ET Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive
More news about: Aethlon Medical, Inc.
Aug 05, 2026, 08:00 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
cGMP production to fill & finish, covering different stages of drug development from early research, Investigator-initiated Clinical Trial Services (IITs), and Investigational New Drug (IND) applications to clinical trials, New Drug Applications (NDA), and commercialization.Porton
More news about: Porton Advanced
Aug 05, 2026, 08:00 ET SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
located in Redmond, WA. It specializes in developing innovative cancer treatments using its established drug development platforms, focusing on bi-specific, multi-specific antibodies, and antibody-drug conjugates (ADCs). SystImmune has several assets in various stages of clinical trials for solid tumor
More news about: SystImmune, Inc.
Aug 05, 2026, 08:00 ET The J.M. Smucker Co. to Report First Quarter Earnings and Participate in the 2026 Barclays Global Consumer Staples Conference
to The J.M. Smucker Co. for packaged coffee products sold in retail channels, such as grocery stores, mass merchandisers, club stores, e-commerce and drug stores, and in certain away from home channels. This information does not pertain to products for sale in Dunkin'® restaurants.
More news about: The J.M. Smucker Co.
Aug 05, 2026, 08:00 ET Neurvati Neurosciences Strengthens Executive Leadership Team to Advance Next Phase of Growth at GRIN Therapeutics
Michael Ryan, M.D., Appointed Chief Medical OfficerDr. Ryan joins Neurvati and GRIN Therapeutics with more than 25 years of neuroscience drug development experience spanning academia, biotechnology, large pharmaceutical companies, and venture-backed organizations. His experience includes leading
More news about: Neurvati Neurosciences
Aug 05, 2026, 08:00 ET Alteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Product
AlteogenAlteogen Inc. is a South Korea-based biopharmaceutical company focused on the development and commercialization of novel biologics, including antibody-drug conjugates (ADCs), biobetters, and biosimilars. Alteogen's pipeline includes clinical-stage long-acting therapeutic proteins and next-generation ADCs
More news about: Alteogen Inc.
Aug 05, 2026, 07:31 ET Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, IITs, Investigational New Drug (IND) applications, clinical trials, New Drug Applications (NDA), to commercialization. Our state-of-the-art, GMP-compliant facilities span
More news about: Porton Advanced
Aug 05, 2026, 07:27 ET Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 46th Annual Growth Conference
sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important
More news about: Cardiol Therapeutics Inc.
Aug 05, 2026, 06:59 ET Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
safety signals, and demonstrated a favorable pharmacokinetic, pharmacodynamic and anti-drug antibody profile. Results from SIGNAL-AA Part B, including additional Week 36 data as well as initial findings from the off-drug period through Week 52, will be presented at a medical meeting in the second half of
More news about: Q32 Bio
Aug 05, 2026, 06:50 ET Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026
produce recombinant proteins in an industrial-scale manner with no exposure to mammalian cells. Protalix is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix has licensed to Pfizer Inc. the
More news about: Protalix BioTherapeutics, Inc.
Aug 05, 2026, 06:45 ET Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress
decrease in realized prices. The lower realized prices outside the U.S. were driven primarily by the addition of Mounjaro to the National Reimbursement Drug List (NRDL) in China. The volume increase outside the U.S. was driven by Mounjaro. Jardiance revenue outside the U.S. included a sales-based milestone
More news about: Eli Lilly and Company
Aug 05, 2026, 06:30 ET CVS HEALTH CORPORATION REPORTS STRONG SECOND QUARTER 2026 RESULTS AND RAISES FULL-YEAR 2026 GUIDANCE
by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.Adjusted operating income increased 10.0% for the three months ended June 30, 2026 compared to the prior year primarily driven by improved purchasing economics, pharmacy drug mix and modest
More news about: CVS Health
Aug 05, 2026, 06:30 ET Zimmer Biomet Announces Second Quarter 2026 Financial Results
in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration ("FDA") and other government regulators relating to medical products, healthcare fraud and abuse laws and data privacy and
More news about: Zimmer Biomet Holdings, Inc.
Aug 05, 2026, 06:00 ET Section 2® Launches as First AML Company to Target Bad Actors and Their Criminal Networks
(FinCEN) eight government-wide AML/CFT priorities: corruption, cybercrime, terrorist financing, fraud, transnational criminal organizations, drug trafficking, human trafficking and smuggling, and proliferation financing.The company also pointed to the "effectiveness rule," a standard under
More news about: Section 2
Aug 05, 2026, 04:00 ET Slone Partners Places Farhad Ghavami as Chief Executive Officer at SeqCenter
joins SeqCenter at a pivotal stage in the company's growth as demand for advanced genomic sequencing technologies and bioinformatics accelerates across drug discovery, precision medicine, research, and healthcare."Farhad Ghavami is a highly-respected life sciences leader with a proven track record
More news about: Slone Partners
Aug 04, 2026, 16:58 ET NIPRO、FDAクリアランス取得を受け、米国医療機関向けに「ELISIO™-HX」を用いた拡張型血液透析を開始
CORPORATIONは、米国に拠点を置く子会社であるNipro Medical Corporationを通じて、本日、スーパーハイフラックス膜技術を採用した中カットオフ型ダイアライザ「ELISIO-HX」の米国での販売開始を発表しました。 このたびELISIO-HXがU.S. Food and Drug Administration（FDA）の510(k)クリアランスを取得したことを受け、NIPROは、スーパーハイフラックス膜を用いた拡張型血液透析法（略称：HDs）を全米の透析医療機関向けに展開しています。この展開は、腎臓医療における重要な節目となります。中分子量物質の除去
More news about: Nipro Medical Corporation
Aug 04, 2026, 16:30 ET Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.
More news about: Azenta
Aug 04, 2026, 16:05 ET Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
dabogratinib is currently advancing in three Phase 2 clinical trials for LG-UTUC (SURF303), IR NMIBC (SURF302), and ACH (BEACH301). The FDA has granted Orphan Drug Designation and Rare Pediatric Disease Designation to oral dabogratinib for the treatment of achondroplasia.Please visit the
More news about: Tyra Biosciences
Aug 04, 2026, 16:05 ET TransMedics Reports Second Quarter 2026 Financial Results
our OCS products in the United States, the European Union and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration (the "FDA") or other competent authorities, follow-up inquiries in a timely manner; the impact of healthcare policy changes, including
More news about: TransMedics Group, Inc.